After nearly 25 years at Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, Prof. Steve Allin has announced he is stepping down as CEO, and will be succeeded by Lee Patterson
Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has launched a new website outlining in detail the company's integrated drug discovery capabilities.
